Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.